TY  - JOUR
U1  - Wissenschaftlicher Artikel
A1  - Pink, Daniel
A1  - Bertz-Lepel, Janina
A1  - Busemann, Christoph
A1  - Bitz, Ulrich
A1  - Reichardt, Peter
T1  - Efficacy of Trabectedin in Patients with Advanced or Metastatic Alveolar Soft-Part Sarcoma
JF  - Oncology Research and Treatment
N2  - Background: Alveolar soft-part sarcoma (ASPS) is a rare sarcoma often occurring in young patients that is characterized by the unbalanced translocation der(17)t(X;17) (p11;q25). Although itusuallyshowsan indolent clinical course, the prognosis is usually poor in advanced disease. Since standard chemotherapy regimens used in soft-tissue sarcomas lack efficacy in ASPS, new therapeutic options are needed. We investigated the efficacy of trabectedin, which has demonstrated activity in a variety of cancer types including some of the most prevalent translocation-related sarcomas. Patients and Methods: 7 patients with metastatic or advanced ASPS treated with trabectedin in the Sarcoma Center Berlin-Brandenburg and the University Hospital of Greifswald were analyzed for median progression-free survival (mPFS), overall survival (OS), and therapy-related toxicity. Results: In 6 patients with documented disease progression, disease stabilization was reached with trabectedin; only 1 patient experienced progressive disease. The mPFS and OS were 7 months and 21 months, respectively, since the start of trabectedin treatment. Overall, no severe Common Toxicity Criteria (CTC) grade 3 or 4 toxicity was observed. Conclusions: The poor prognosis of patients with ASPS has so far been due to the unavailability of effective systemic treatments. Trabectedin can be considered the only currently registered drug with clinical activity in this disease.
KW  - -
KW  - Trabectedin
KW  - ASPS
Y1  - 2012
UN  - https://nbn-resolving.org/urn:nbn:de:gbv:9-opus-31042
UR  - www.karger.com/onk
SN  - 2296-5270
SS  - 2296-5270
SN  - 2296-5262
SS  - 2296-5262
U6  - https://doi.org/10.1159/000338342
DO  - https://doi.org/10.1159/000338342
PM  - 22868503
VL  - 35
IS  - 5
SP  - 249
EP  - 252
PB  - S. Karger AG
CY  - Basel, Switzerland
ER  -